Postoperative Thrombosis Prevention in Patients With CD

• Status: Recruiting
• Trial end date: 2023-07-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients with Cushing disease was randomized to 2 groups. After surgery, the patients were managed with mechanical prevention or mechanical prevention plus anticoagulant drugs(LMWH followed by rivaroxaban), VTE was observed 24h, 5day, 4weeks and 12weeks after surgery.Bleeding events were also recorded.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huashan Hospital
• Collaborators: Peking Union Medical College Hospital; West China Hospital
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Cushing's disease patient diagnosed and treated with transsphenoid surgery at study centers

Exclusion Criteria:

• patients with thrombosis before surgery;

• patients with cute bacterial endocarditis,

• thrombocytopenia,

• active peptic ulcer,

• with contraindications to Rivaroxaban;

• patients whose cranial MRA or CTA prompts abnormalities in intracranial blood vessels which may be at risk of intracranial hemorrhage;

• patients with coagulation abnormalities suggesting a high risk of bleeding